GSK2982772 Study in Subjects With Ulcerative Colitis

Status Completed

Clinical Trial Summary

This study is the first experience with GSK2982772, a receptor-interacting protein-1 (RIP1) kinase inhibitor, in subjects with active ulcerative colitis (UC). The primary objective will be to investigate the safety and tolerability of repeat oral doses of GSK2982772 60 mg or placebo three times daily for 42 days (Part A) followed by open label with GSK298772 60 mg three times daily for 42 days (Part B). In addition to pharmacokinetics (PK), a number of experimental and clinical endpoints will be employed to obtain information on the pharmacodynamics (PD), and preliminary efficacy in subjects with active UC. Although no formal hypothesis will be tested, these endpoints will enable a broader understanding of the mechanism of action and potential for clinical efficacy of GSK2982772 in UC. Within 30 Days of screening visit, subjects will be randomized to receive either GSK2982772 60 mg or placebo orally three times daily for 42 Days (6 weeks) in a 2:1 ratio in Part A study. Subjects who complete the Part A study will move to open label Part B study to receive GSK2982772 60 mg three times daily for an additional 42 Days (6 weeks). After the open label (Part B) treatment period, subjects will enter the Follow-up period which lasts for 28 Days (+/- 3 Days) post the last administration of study medication. The total duration of participation in the study will be approximately 20 Weeks from screening to the last study visit.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02903966
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 2
Start date	November 15, 2016
Completion date	June 17, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04989907` - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Completed	`NCT03494764` - Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares	Phase 2
Recruiting	`NCT03937609` - TITRATE (inducTIon for acuTe ulceRATivE Colitis)	Phase 4
Completed	`NCT00503243` - Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis	Phase 3
Completed	`NCT03606499` - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Completed	`NCT02537210` - Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis	N/A
Active, not recruiting	`NCT02316678` - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics	N/A
Completed	`NCT00488631` - An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT00928681` - A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis	Phase 1
Recruiting	`NCT05242484` - A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2
Completed	`NCT01036022` - Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis	Phase 2
Recruiting	`NCT03841045` - Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
Active, not recruiting	`NCT05528510` - A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT02825914` - CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)	N/A
Recruiting	`NCT06049017` - A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2
Completed	`NCT04567628` - Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
Withdrawn	`NCT05999708` - A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants	Phase 1
Recruiting	`NCT05611671` - A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC	Phase 2
Active, not recruiting	`NCT03596645` - A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT03648541` - BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis	Phase 2